ES515455A0 - "un procedimiento para preparar una solucion oftalmica anti-inflamatoria a base de un derivado del acido propionico y una ciclodextrina". - Google Patents

"un procedimiento para preparar una solucion oftalmica anti-inflamatoria a base de un derivado del acido propionico y una ciclodextrina".

Info

Publication number
ES515455A0
ES515455A0 ES515455A ES515455A ES515455A0 ES 515455 A0 ES515455 A0 ES 515455A0 ES 515455 A ES515455 A ES 515455A ES 515455 A ES515455 A ES 515455A ES 515455 A0 ES515455 A0 ES 515455A0
Authority
ES
Spain
Prior art keywords
cyclodextrin
preparing
procedure
propionic acid
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES515455A
Other languages
English (en)
Other versions
ES8401849A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kakenyaku Kako KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kakenyaku Kako KK filed Critical Kakenyaku Kako KK
Publication of ES515455A0 publication Critical patent/ES515455A0/es
Publication of ES8401849A1 publication Critical patent/ES8401849A1/es
Expired legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES515455A 1981-12-24 1982-09-02 "un procedimiento para preparar una solucion oftalmica anti-inflamatoria a base de un derivado del acido propionico y una ciclodextrina". Expired ES8401849A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56214189A JPS58126810A (ja) 1981-12-24 1981-12-24 抗炎症眼科用液剤およびその製法

Publications (2)

Publication Number Publication Date
ES515455A0 true ES515455A0 (es) 1984-01-01
ES8401849A1 ES8401849A1 (es) 1984-01-01

Family

ID=16651708

Family Applications (1)

Application Number Title Priority Date Filing Date
ES515455A Expired ES8401849A1 (es) 1981-12-24 1982-09-02 "un procedimiento para preparar una solucion oftalmica anti-inflamatoria a base de un derivado del acido propionico y una ciclodextrina".

Country Status (12)

Country Link
US (1) US4474811A (es)
EP (1) EP0082921B1 (es)
JP (1) JPS58126810A (es)
AT (1) AT385201B (es)
AU (1) AU549419B2 (es)
CA (1) CA1182751A (es)
CH (1) CH652598A5 (es)
DE (1) DE3274187D1 (es)
DK (1) DK570482A (es)
ES (1) ES8401849A1 (es)
IE (1) IE54467B1 (es)
ZA (1) ZA829410B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
JPS5929616A (ja) * 1982-08-10 1984-02-16 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS60184013A (ja) * 1984-03-01 1985-09-19 Yoshitomi Pharmaceut Ind Ltd 点眼剤
US5266563A (en) * 1984-06-11 1993-11-30 Biomatrix, Inc. Hyakyribate-poly (ethylene oxide) mixtures
US4629623A (en) * 1984-06-11 1986-12-16 Biomatrix, Inc. Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
JPS62270521A (ja) * 1986-05-16 1987-11-24 Green Cross Corp:The フルルビプロフエン眼投与製剤
JP2764261B2 (ja) * 1987-03-17 1998-06-11 リ−ドケミカル株式会社 外用消炎鎮痛剤
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
JPH07508716A (ja) * 1992-04-21 1995-09-28 ザ スキーペンズ アイ リサーチ インスティテュート,インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5362758A (en) * 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
US5382599A (en) * 1993-10-13 1995-01-17 Allergan, Inc. Method of inhibiting protozoan growth in eye care products using a polyvalent cation chelating agent
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
CA2192965C (en) * 1994-07-11 2007-12-04 David W. Pate Anandamide analogue compositions and method of treating intraocular hypertension using same
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
AU2016201834A1 (en) * 2002-07-30 2016-04-14 Omeros Corporation Ophthalmologic irrigation solutions and method
CN101327325A (zh) 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
PT2921171T (pt) * 2014-03-21 2020-01-21 Epitech Group S P A Preparações oftálmicas, intra-articulares ou intravesicais contendo n-acil-etanolaminas
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1359987A (en) * 1970-10-12 1974-07-17 Boots Co Ltd 2-substituted biphenylyl propionic acids
US4202988A (en) * 1977-03-30 1980-05-13 American Cyanamid Company Prostenoic acids and esters
JPS5528904A (en) * 1978-08-18 1980-02-29 Mitsubishi Petrochem Co Ltd Preparation of biphenyl derivative
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
JPS5634618A (en) * 1979-08-30 1981-04-06 Ota Seiyaku Kk Production of flurbiprofen preparation
JPS5646838A (en) * 1979-09-27 1981-04-28 Mitsubishi Yuka Yakuhin Kk 2- 2-fluoro-4-biphenylyl propionic acid-cyclodextrin clathrate compound
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
US4379792A (en) * 1980-10-30 1983-04-12 Merck & Co., Inc. Anti-inflammatory composition

Also Published As

Publication number Publication date
DK570482A (da) 1983-06-25
CA1182751A (en) 1985-02-19
EP0082921B1 (en) 1986-11-12
ATA464382A (de) 1987-08-15
US4474811A (en) 1984-10-02
ZA829410B (en) 1983-10-26
JPS58126810A (ja) 1983-07-28
EP0082921A1 (en) 1983-07-06
AU549419B2 (en) 1986-01-23
IE54467B1 (en) 1989-10-25
IE823020L (en) 1983-06-24
AT385201B (de) 1988-03-10
ES8401849A1 (es) 1984-01-01
CH652598A5 (de) 1985-11-29
AU9175282A (en) 1983-06-30
DE3274187D1 (en) 1987-01-02

Similar Documents

Publication Publication Date Title
ES515455A0 (es) "un procedimiento para preparar una solucion oftalmica anti-inflamatoria a base de un derivado del acido propionico y una ciclodextrina".
ES524900A0 (es) Procedimiento para preparar 9-(1,3-dihidroxi-2-propoximetil)-guanina y sus sales farmaceuticamente aceptables.
ES520670A0 (es) Un procedimiento para la preparacion de derivados de acidos alcanoicos.
ES510348A0 (es) "procedimiento de preparacion de nuevos derivados 3,4-dihidro-5h-2,3-benzodiazepinos y de sus sales de adicion acidas farmaceuticamente aceptables".
NL192561B (nl) Oogontstekings-werende middelen. Oftalmische preparaten die bepaalde fenylazijnzuurverbindingen bevatten.
ES516438A0 (es) "un procedimiento para preparar un derivado de -(4-(2-piridil)-pi-peracino)-alcanoilanilida".
ES508337A0 (es) Un procedimiento para la preparacion de un isomero (25) del acido 2-(4-(2-hidroxiciclopentan-1-ilmetil)fenil)propionico.
AR242560A1 (es) Un procedimiento para producir derivados de acidos 1-amidin-piperidin-alcanoicos y sus sales farmaceuticamente aceptables.
ES521430A0 (es) Un procedimiento para la preparacion de derivados del acido tetrahidrofurancarboxilico.
GB2021583B (en) Process for preparing 2-(6'-methoxy-2'naphthyl propionic acid
IT1207155B (it) Derivati di acidi prostanoici 4,5insaturi
ES518969A0 (es) Un procedimiento para la preparacion de derivados de 1,1-dioxido del acido penicilanico.
ES500032A0 (es) Un procedimiento para la preparacion de derivados del acido 7-oxo-1-azabiciclo (3,2,0) hept-2-en-2-carboxilico.
ES481233A0 (es) Un procedimiento para la preparacion de derivados del acido 4,5-dihidro-4-oxofuran-2-carboxilico
ES513074A0 (es) "procedimiento para la polimerizacion de una 1-olefina".
GB2027015B (en) 2-(p-prenylphenyl) propionic acid
ES500938A0 (es) Un procedimiento para la preparacion de nuevos derivados del acido acetico.
ES488211A0 (es) Un procedimiento para la preparacion del acido 7-oxo-1-aza- biciclo (3.2.0)hept-2-en-2-carboxilico
AU530911B2 (en) 2-(2-phenyl-6-benzothiazolyl) propionic acid
ES508346A0 (es) Un procedimiento para la preparacion de derivados del acido 2 beta-clorometil-2 alfa-metilpenam-3 alfa-carboxilico.
IE45148L (en) Optically active 2-(2-phenyl-5-benzoxazolyl) propionic acids
ES513075A0 (es) "procedimiento para la polimerizacion de una 1-olefina".
ES516054A0 (es) "procedimiento para preparar esteres del acido vincaminico racemicos y opticamente activos".
ES523685A0 (es) Un procedimiento para preparar derivados de eter de eburnano-oxima racemicos u opticamente activos.
ES485079A0 (es) Un procedimiento para la preparacion del acido d-alfa-amino-alfa-(3,4-dihidroxifenil) acetamidopenicilanico.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19981103